Skip to content
2000
Volume 32, Issue 16
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Introduction

Colon cancer is a frequent malignancy, and surgery is still the primary therapy for people with colon cancer. Other treatments, including radiation, chemotherapy, and biologic therapy, may be utilized as a supplement. Chemotherapy, a prominent treatment for colon cancer, has failed to provide positive outcomes. This necessitates the development of more effective and less harmful treatment drugs. Coptisine was discovered to inhibit the development of colon cancer cell line HCT-116 , decrease the growth of HCT-116 cells, and cause apoptosis in colon cancer. Coptisine (COP) has shown antitumor activity in colon cancer, but its molecular mechanism and its molecular targets have not been fully understood.

Methods

In this study, the biological behavior was verified . The targets of Huanglian alkaloids on colon cancer were predicted, and the protein-protein interaction (PPI) network was constructed. The core targets of safranine for colon cancer were extracted and analyzed by GO and KEGG enrichment to identify the possible molecular mechanisms of safranine treatment. Western blot was used to detect the changes of related pathway proteins in colon cancer cells. The differential expression of hub genes in colon cancer was analyzed using the GEPIA2 website. The binding ability of safranine to the target was verified by molecular docking. Finally, the targets were preliminarily verified by q-PCR analysis.

Results

Coptisine can inhibit the survival, migration, and proliferation of colon cancer cells DLD1 and HCT-116. Based on network pharmacology, ninety-one targets for colon cancer were screened. ESR1, ALB, AR, CDK2, PARP1, HSP90AB1, IGF1R, CCNE1, and CDC42 were found in the top 10. Enrichment analysis showed that these targets were mainly related to pathways in cancer, FC γ R-mediated phagocytosis, prostate cancer, progesterone-mediated oocyte maturation, the oestrogen signal pathway, proteoglycan in cancer and the PI3K-Akt signal pathway. WB results showed that after the treatment of colon cancer DLD1 cells with coptisine, the expression of P-AKT and AKT decreased, that of its downstream protein Bcl-2 decreased, and that of BAX increased. Differential expression analysis of hub genes showed that CCNE1, CDK2, HSP90AB1, and CHEK2 were upregulated in colon cancer samples, and molecular docking showed that these targets had a good ability to bind to coptisine. After the treatment of colon cancer DLD1 cells with coptisine, q-PCR results showed that CCNE1 and HSP90AB1 were significantly downregulated, while CDK2 and CHEK2 had no significant changes.

Conclusion

Coptisine may be a candidate drug for the treatment of colon cancer, and its therapeutic effect may be related to the cancer pathway and PI3K-Akt signalling pathway. CCNE1 and HSP90AB1 may be potential targets of coptisine in the treatment of colon cancer.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673262553231227075800
2024-01-12
2026-02-27

  • From This Site

    /content/journals/cmc/10.2174/0109298673262553231227075800
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.2149230207593
     [Google Scholar]
  2. WangQ. LiZ. GuoJ. LiW. YouF. Effect of Chinese herbal medicine formula on progression-free survival among patients with metastatic colorectal cancer: Study protocol for a multi-center, double-blinded, randomized, placebo-controlled trial.PLoS One20221712e027505810.1371/journal.pone.027505836525406
     [Google Scholar]
  3. JangJ.Y. ImE. KimN.D. Therapeutic potential of bioactive components from Scutellaria baicalensis georgi in inflammatory bowel disease and colorectal cancer: A review.Int. J. Mol. Sci.2023243195410.3390/ijms2403195436768278
     [Google Scholar]
  4. TangX. LiangY. FengX. ZhangR. JinX. SunL. Co-delivery of docetaxel and Poloxamer 235 by PLGA–TPGS nanoparticles for breast cancer treatment.Mater. Sci. Eng. C20154934835510.1016/j.msec.2015.01.03325686959
     [Google Scholar]
  5. WangZ. ChenZ. YangS. WangY. HuangZ. GaoJ. TuS. RaoZ. Berberine ameliorates collagen-induced arthritis in rats associated with anti-inflammatory and anti-angiogenic effects.Inflammation20143751789179810.1007/s10753‑014‑9909‑y24803296
     [Google Scholar]
  6. XiaX. YanJ. ShenY. TangK. YinJ. ZhangY. YangD. LiangH. YeJ. WengJ. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis.PLoS One201162e1655610.1371/journal.pone.001655621304897
     [Google Scholar]
  7. HuY. EhliE.A. KittelsrudJ. RonanP.J. MungerK. DowneyT. BohlenK. CallahanL. MunsonV. JahnkeM. MarshallL.L. NelsonK. HuizengaP. HansenR. SoundyT.J. DaviesG.E. Lipid-lowering effect of berberine in human subjects and rats.Phytomedicine2012191086186710.1016/j.phymed.2012.05.00922739410
     [Google Scholar]
  8. ZhangL. MiaoX.J. WangX. PanH.H. LiP. RenH. JiaY.R. LuC. WangH.B. YuanL. ZhangG.L. Antiproliferation of berberine is mediated by epigenetic modification of constitutive androstane receptor (CAR) metabolic pathway in hepatoma cells.Sci. Rep.2016612811610.1038/srep2811627311637
     [Google Scholar]
  9. LiuX. JiQ. YeN. SuiH. ZhouL. ZhuH. FanZ. CaiJ. LiQ. Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE2 mediated JAK2/STAT3 signaling pathway.PLoS One2015105e012347810.1371/journal.pone.012347825954974
     [Google Scholar]
  10. Qin-WeiZ.H.U. Yong-GuangL.I. Berberine attenuates myocardial ischemia reperfusion injury by suppressing the activation of PI3K/AKT signaling.Exp. Ther. Med.201611397898410.3892/etm.2016.301826998023
     [Google Scholar]
  11. LiuX. ZhangX. YeL. YuanH. Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model.Biomed. Pharmacother.20167922223010.1016/j.biopha.2016.02.01527044832
     [Google Scholar]
  12. LangL. HuQ. WangJ. LiuZ. HuangJ. LuW. HuangY. Coptisine, a natural alkaloid from Coptidis Rhizoma, inhibits Plasmodium falciparum dihydroorotate dehydrogenase.Chem. Biol. Drug Des.20189211324133210.1111/cbdd.1319729582555
     [Google Scholar]
  13. LiC. HuangP. WongK. XuY. TanL. ChenH. LuQ. LuoC. TamC. ZhuL. SuZ. XieJ. Coptisine-induced inhibition of Helicobacter pylori : Elucidation of specific mechanisms by probing urease active site and its maturation process.J. Enzyme Inhib. Med. Chem.20183311362137510.1080/14756366.2018.150104430191728
     [Google Scholar]
  14. WangY. WangQ. ZhangL. KeZ. ZhaoY. WangD. ChenH. JiangX. GuM. FanS. HuangC. Coptisine protects cardiomyocyte against hypoxia/reoxygenation-induced damage via inhibition of autophagy.Biochem. Biophys. Res. Commun.2017490223123810.1016/j.bbrc.2017.06.02728606475
     [Google Scholar]
  15. WuJ. ZhangH. HuB. YangL. WangP. WangF. MengX. Coptisine from Coptis chinensis inhibits production of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 murine macrophage cells.Eur. J. Pharmacol.201678010611410.1016/j.ejphar.2016.03.03727018392
     [Google Scholar]
  16. FuS. NiS. WangD. HongT. Coptisine suppresses mast cell degranulation and ovalbumin-induced allergic rhinitis.Molecules20182311303910.3390/molecules2311303930469322
     [Google Scholar]
  17. ZhouK. HuL. LiaoW. YinD. RuiF. Coptisine prevented IL-β-induced expression of inflammatory mediators in chondrocytes.Inflammation20163941558156510.1007/s10753‑016‑0391‑627294276
     [Google Scholar]
  18. ZhangY.L. ZhangX. MiaoX.Z. YuanY.Y. GaoJ. LiX. LiuY.G. TanP. Coptisine suppresses proliferation and inhibits metastasis in human pancreatic cancer PANC-1 cells.J. Asian Nat. Prod. Res.202022545246310.1080/10286020.2019.158582031119952
     [Google Scholar]
  19. KimS.Y. HwangboH. KimM.Y. JiS.Y. LeeH. KimG.Y. KwonC.Y. LeemS.H. HongS.H. CheongJ. ChoiY.H. Coptisine induces autophagic cell death through down-regulation of PI3K/Akt/mTOR signaling pathway and up-regulation of ROS-mediated mitochondrial dysfunction in hepatocellular carcinoma Hep3B cells.Arch. Biochem. Biophys.202169710868810.1016/j.abb.2020.10868833227289
     [Google Scholar]
  20. ChaiF.N. MaW.Y. ZhangJ. XuH.S. LiY.F. ZhouQ.D. LiX.G. YeX.L. Coptisine from Rhizoma coptidis exerts an anti-cancer effect on hepatocellular carcinoma by up-regulating miR-122.Biomed. Pharmacother.20181031002101110.1016/j.biopha.2018.04.05229710498
     [Google Scholar]
  21. ZhouL. YangF. LiG. HuangJ. LiuY. ZhangQ. TangQ. HuC. ZhangR. Coptisine induces apoptosis in human hepatoma cells through activating 67-kDa Laminin Receptor/cGMP Signaling.Front. Pharmacol.2018951710.3389/fphar.2018.0051729867512
     [Google Scholar]
  22. KimS.Y. HwangboH. LeeH. ParkC. KimG.Y. MoonS.K. YunS.J. KimW.J. CheongJ. ChoiY.H. Induction of apoptosis by coptisine in hep3b hepatocellular carcinoma cells through activation of the ROS-Mediated JNK signaling pathway.Int. J. Mol. Sci.20202115550210.3390/ijms2115550232752099
     [Google Scholar]
  23. WenX. ZhangX. QuS. ChenX. LiuC. YangY. Coptisine induces G2/M arrest in esophageal cancer cell via the inhibition of p38/ERK1/2/claudin-2 signaling pathway.Pharmazie2021765202207[From NLM.].10.1691/ph.2021.135333964993
     [Google Scholar]
  24. HuangT. XiaoY. YiL. LiL. WangM. TianC. MaH. HeK. WangY. HanB. YeX. LiX. Coptisine from Rhizoma coptidis suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo .Sci. Rep.2017713852410.1038/srep3852428165459
     [Google Scholar]
  25. HanB. JiangP. LiZ. YuY. HuangT. YeX. LiX. Coptisine-induced apoptosis in human colon cancer cells (HCT-116) is mediated by PI3K/Akt and mitochondrial-associated apoptotic pathway.Phytomedicine20184815216010.1016/j.phymed.2017.12.02730195873
     [Google Scholar]
  26. HopkinsA.L. Network pharmacology.Nat. Biotechnol.200725101110111110.1038/nbt1007‑111017921993
     [Google Scholar]
  27. YangL. LiH. YangM. ZhangW. LiM. XuY. LiJ. KangJ. ZhangJ. GuoS. Exploration in the mechanism of kaempferol for the treatment of gastric cancer based on network pharmacology.Bio. Med. Res. Int.2020202011110.1155/2020/589101633145355
     [Google Scholar]
  28. ZhuJ. LiB. JiY. ZhuL. ZhuY. ZhaoH. β-elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A-VEGFA pathway based on network pharmacology.Oncol. Rep.20194262561257110.3892/or.2019.736031638231
     [Google Scholar]
  29. ZengC.Y. ZhanY.S. HuangJ. ChenY.X. MicroRNA-7 suppresses human colon cancer invasion and proliferation by targeting the expression of focal adhesion kinase.Mol. Med. Rep.20161321297130310.3892/mmr.2015.464326648422
     [Google Scholar]
  30. LiX. TangH. TangQ. ChenW. Decoding the mechanism of huanglian jiedu decoction in treating pneumonia based on network pharmacology and molecular docking.Front. Cell. Dev. Biol.2021963836610.3389/fcell.2021.63836633681222
     [Google Scholar]
  31. FanW. GaoX. DingC. LvY. ShenT. MaG. YanL. SongS. Estrogen receptors participate in carcinogenesis signaling pathways by directly regulating NOD-like receptors.Biochem. Biophys. Res. Commun.2019511246847510.1016/j.bbrc.2019.02.08530797557
     [Google Scholar]
  32. LiuS. FanW. GaoX. HuangK. DingC. MaG. YanL. SongS. Estrogen receptor alpha regulates the Wnt/β-catenin signaling pathway in colon cancer by targeting the NOD-like receptors.Cell. Signal.201961869210.1016/j.cellsig.2019.05.00931121307
     [Google Scholar]
  33. SlatteryM.L. SweeneyC. MurtaughM. MaK.N. WolffR.K. PotterJ.D. CaanB.J. SamowitzW. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer.Cancer Epidemiol. Biomarkers Prev.200514122936294210.1158/1055‑9965.EPI‑05‑051416365013
     [Google Scholar]
  34. BoonpipattanapongT. ChewatanakornkulS. Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas.J. Clin. Gastroenterol.200640759259510.1097/00004836‑200608000‑0000616917399
     [Google Scholar]
  35. KoffA. GiordanoA. DesaiD. YamashitaK. HarperJ.W. ElledgeS. NishimotoT. MorganD.O. FranzaB.R. RobertsJ.M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.Science199225750771689169410.1126/science.13882881388288
     [Google Scholar]
  36. ZhaoY. HuX. ZuoX. WangM. Chemopreventive effects of some popular phytochemicals on human colon cancer: A review.Food Funct.2018994548456810.1039/C8FO00850G30118121
     [Google Scholar]
  37. LiX. HanF. LiuW. ShiX. PTBP1 promotes tumorigenesis by regulating apoptosis and cell cycle in colon cancer.Bull. Cancer2018105121193120110.1016/j.bulcan.2018.08.01330309622
     [Google Scholar]
  38. PatelH.J. ModiS. ChiosisG. TaldoneT. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.Expert Opin. Drug Discov.20116555958710.1517/17460441.2011.56329622400044
     [Google Scholar]
  39. WhitesellL. LindquistS.L. HSP90 and the chaperoning of cancer.Nat. Rev. Cancer200551076177210.1038/nrc171616175177
     [Google Scholar]
  40. WorkmanP. BurrowsF. NeckersL. RosenN. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress.Ann. N. Y. Acad. Sci.20071113120221610.1196/annals.1391.01217513464
     [Google Scholar]
  41. ZuehlkeA. JohnsonJ.L. Hsp90 and co‐chaperones twist the functions of diverse client proteins.Biopolymers201093321121710.1002/bip.2129219697319
     [Google Scholar]
  42. WangH. DengG. AiM. XuZ. MouT. YuJ. LiuH. WangS. LiG. Hsp90ab1 stabilizes LRP5 to promote epithelial–mesenchymal transition via activating of AKT and Wnt/β-catenin signaling pathways in gastric cancer progression.Oncogene20193891489150710.1038/s41388‑018‑0532‑530305727
     [Google Scholar]
  43. ZongR. ChenX. FengJ. XuS. IGF-1R depletion sensitizes colon cancer cell lines to radiotherapy.Cancer Biomark.202132219920610.3233/CBM‑21001634092618
     [Google Scholar]
  44. LiX.X. HuangL.Y. PengJ.J. LiangL. ShiD.B. ZhengH.T. CaiS.J. Klotho suppresses growth and invasion of colon cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway.Int. J. Oncol.201445261161810.3892/ijo.2014.243024818842
     [Google Scholar]
  45. CybulskiC. GórskiB. HuzarskiT. MasojćB. MierzejewskiM. DębniakT. TeodorczykU. ByrskiT. GronwaldJ. MatyjasikJ. ZłowockaE. LennerM. GrabowskaE. NejK. CastanedaJ. MędrekK. SzymańskaA. SzymańskaJ. KurzawskiG. SuchyJ. OszurekO. WitekA. NarodS.A. LubińskiJ. CHEK2 is a multiorgan cancer susceptibility gene.Am. J. Hum. Genet.20047561131113510.1086/42640315492928
     [Google Scholar]
  46. FukataM. WatanabeT. NoritakeJ. NakagawaM. YamagaM. KurodaS. MatsuuraY. IwamatsuA. PerezF. KaibuchiK. Rac1 and Cdc42 capture microtubules through IQGAP1 and CLIP-170.Cell2002109787388510.1016/S0092‑8674(02)00800‑012110184
     [Google Scholar]
  47. ReymondN. ImJ.H. GargR. VegaF.M. Borda d’AguaB. RiouP. CoxS. ValderramaF. MuschelR.J. RidleyA.J. Cdc42 promotes transendothelial migration of cancer cells through β1 integrin.J. Cell Biol.2012199465366810.1083/jcb.20120516923148235
     [Google Scholar]
  48. StengelK.R. ZhengY. Essential role of Cdc42 in Ras-induced transformation revealed by gene targeting.PLoS One201276e3731710.1371/journal.pone.003731722719838
     [Google Scholar]
  49. Gómez del PulgarT. Valdés-MoraF. BandrésE. Pérez-PalaciosR. EspinaC. CejasP. García-CabezasM. NistalM. CasadoE. González-BarónM. García-FoncillasJ. LacalJ. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.Int. J. Oncol.200833118519310.3892/ijo.33.1.18518575765
     [Google Scholar]
  50. SakamoriR. YuS. ZhangX. HoffmanA. SunJ. DasS. VedulaP. LiG. FuJ. WalkerF. YangC.S. YiZ. HsuW. YuD.H. ShenL. RodriguezA.J. TaketoM.M. BonderE.M. VerziM.P. GaoN. CDC42 inhibition suppresses progression of incipient intestinal tumors.Cancer Res.201474195480549210.1158/0008‑5472.CAN‑14‑026725113996
     [Google Scholar]
  51. HennessyB.T. SmithD.L. RamP.T. LuY. MillsG.B. Exploiting the PI3K/AKT pathway for cancer drug discovery.Nat. Rev. Drug Discov.2005412988100410.1038/nrd190216341064
     [Google Scholar]
  52. LiZ. ZhouX. ZhuH. SongX. GaoH. NiuZ. LuJ. Purpurin binding interacts with LHPP protein that inhibits PI3K/AKT phosphorylation and induces apoptosis in colon cancer cells HCT‐116.J. Biochem. Mol. Toxicol.2021353e2266510.1002/jbt.2266533368780
     [Google Scholar]
  53. HeQ. LiuC. WangX. RongK. ZhuM. DuanL. ZhengP. MiY. Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking.Front. Pharmacol.202314110258110.3389/fphar.2023.110258136874006
     [Google Scholar]
  54. BartekJ. LukasJ. Chk1 and Chk2 kinases in checkpoint control and cancer.Cancer Cell20033542142910.1016/S1535‑6108(03)00110‑712781359
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673262553231227075800
Loading
Exploring the Molecular Targets and Therapeutic Potential of Coptisine in Colon Cancer: A Network Pharmacology Approach
Curr. Med. Chem. 32, 3295 (2025); https://doi.org/10.2174/0109298673262553231227075800
/content/journals/cmc/10.2174/0109298673262553231227075800
/content/journals/cmc/10.2174/0109298673262553231227075800
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): CCNE1; colon cancer; Coptisine; HSP90AB1; molecular docking; network pharmacology; PI3K-Akt

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test